<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Causes of primary adrenal insufficiency (Addison disease)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Causes of primary adrenal insufficiency (Addison disease)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Causes of primary adrenal insufficiency (Addison disease)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynnette K Nieman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">André Lacroix, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>When Thomas Addison described the disease that now bears his name [<a href="#rid1">1</a>], bilateral adrenal destruction by tuberculosis was its most common cause. Now tuberculosis accounts for only 7 to 20 percent of cases; autoimmune disease is responsible for 70 to 90 percent, with the remainder being caused by other infectious diseases, replacement by metastatic cancer or lymphoma, adrenal hemorrhage or infarction, or drugs  (<a class="graphic graphic_table graphicRef52048" href="/d/graphic/52048.html" rel="external">table 1</a>) [<a href="#rid2">2-6</a>]. Disseminated tuberculous or fungal infections are still a major cause of adrenal insufficiency in populations with a high prevalence of these diseases, but as tuberculosis has been better controlled, the overall incidence of Addison disease has decreased [<a href="#rid7">7</a>]. The prevalence of Addison disease in Western countries has been estimated at 35 to 60 per million, but three studies indicate it may be as high as 144 per million [<a href="#rid8">8-10</a>].</p><p>This topic will review the major causes of primary adrenal insufficiency. The pathogenesis, clinical manifestations, diagnosis, and treatment of adrenal insufficiency are reviewed separately. Other rare causes of adrenal insufficiency, such as adrenoleukodystrophy/adrenal myeloneuropathy, inherited disorders that present in infancy or childhood are also reviewed separately  (<a class="graphic graphic_table graphicRef52048" href="/d/graphic/52048.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/169.html" rel="external">"Pathogenesis of autoimmune adrenal insufficiency"</a> and  <a class="medical medical_review" href="/d/html/159.html" rel="external">"Clinical manifestations of adrenal insufficiency in adults"</a> and  <a class="medical medical_review" href="/d/html/154.html" rel="external">"Determining the etiology of adrenal insufficiency in adults"</a> and  <a class="medical medical_review" href="/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults"</a> and  <a class="medical medical_review" href="/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">AUTOIMMUNE ADRENALITIS</span><span class="headingEndMark"> — </span>What long was termed "idiopathic" primary adrenal insufficiency is the result of an autoimmune process that destroys the adrenal cortex. There is evidence of both humoral and cell-mediated immune mechanisms directed at the adrenal cortex, often associated with autoimmune destruction of other endocrine glands (referred to as polyglandular autoimmune syndromes). Antibodies that react with several steroidogenic enzymes (most often 21-hydroxylase) and all three zones of the adrenal cortex are present in the serum of up to 86 percent of patients with autoimmune primary adrenal insufficiency (anti-21-hydroxylase [<a href="#rid10">10</a>]), but only rarely in patients with other causes of adrenal insufficiency, or in normal subjects [<a href="#rid10">10,11</a>]. However, up to 10 percent of first-degree relatives of patients with autoimmune primary adrenal insufficiency express these antibodies and have an increased risk of developing adrenal insufficiency [<a href="#rid11">11</a>].</p><p>Patients who develop isolated autoimmune adrenal insufficiency during the first two decades of life are predominately male (71 percent), whereas those diagnosed during the third decade are equally male and female, and those diagnosed thereafter are predominately female (81 percent) [<a href="#rid12">12</a>]. The explanation for these sex differences is unknown.</p><p class="headingAnchor" id="H1925564"><span class="h2">Initial laboratory findings</span><span class="headingEndMark"> — </span>The first evidence of autoimmune adrenal insufficiency is usually an increase in plasma renin activity in association with a normal or low serum aldosterone concentration, suggesting that the zona glomerulosa is involved initially [<a href="#rid13">13,14</a>]. Several months to years later, zona fasciculata dysfunction becomes evident, first by a decreasing serum cortisol response to corticotropin (ACTH) stimulation, later by increased basal serum ACTH concentrations, and finally by decreasing basal serum cortisol concentrations and symptoms [<a href="#rid13">13,15</a>].</p><p>One study suggests that a rise in serum ACTH is the best predictor of the subsequent development of adrenal insufficiency in patients with 21-hydroxylase autoantibodies. This was illustrated in a report of 87 such individuals (excluding polyglandular autoimmune syndrome type 1 patients), who were prospectively followed for the development of adrenal insufficiency. In this cohort, seven individuals developed adrenal insufficiency while 80 did not. When compared with nonprogressors, those who progressed to adrenal insufficiency were more likely to have an elevated serum ACTH, but there were no differences in plasma renin activity or peak cortisol response to exogenous ACTH [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H1925585"><span class="h2">Polyglandular autoimmune syndromes</span><span class="headingEndMark"> — </span>The combination of autoimmune adrenal insufficiency with other autoimmune endocrine disorders have been referred to as the polyglandular autoimmune syndromes types 1 and 2 [<a href="#rid17">17-20</a>]. Approximately 50 to 65 percent of patients with autoimmune adrenal insufficiency have one or more other autoimmune endocrine disorders  (<a class="graphic graphic_table graphicRef69574" href="/d/graphic/69574.html" rel="external">table 2</a>) [<a href="#rid2">2,3,10,21-24</a>]. On the other hand, patients with the more common autoimmune endocrine disorders (such as type 1 [insulin-dependent] diabetes mellitus, chronic autoimmune thyroiditis, or Graves' disease) rarely develop adrenal insufficiency. In one report, as an example, 11 of 629 patients (1.7 percent) with type 1 diabetes but none of 239 healthy individuals had antibodies directed against 21-hydroxylase [<a href="#rid25">25</a>]. Of the 11 patients with anti-21-hydroxylase antibodies, three had adrenal insufficiency, five did not, and three had not been tested. In another study, only 1 of 114 children with type 1 diabetes and none of 35 children with autoimmune thyroiditis tested positive for anti-adrenal antibodies measured by immunofluorescence [<a href="#rid26">26</a>].</p><p>In contrast, approximately 80 percent of patients with diabetes mellitus associated with the DQ8 HLA allele who also have the DRB*0404 HLA allele and autoantibodies against 21-hydroxylase develop adrenal insufficiency [<a href="#rid27">27,28</a>]. In another report of 38 patients with type 1 diabetes who also had antibodies directed against 21-hydroxylase, those who were homozygous for MICA5.1 (an MHC class I-related molecule located between tumor necrosis factor-alpha and HLA-B) were at higher risk for developing adrenal insufficiency than those without homozygosity [<a href="#rid28">28,29</a>].</p><p>Adrenal insufficiency is easily diagnosed and treated, and it is potentially lethal if unrecognized; this has led some investigators to recommend screening for this disorder in all patients with type 1 diabetes. Nevertheless, we do not believe that testing this large patient population is warranted, given the approximately 1 percent prevalence of subnormal responses to ACTH in these patients.</p><p>Patients with celiac disease had an 11-fold increased risk for adrenal insufficiency in a Swedish study, and 6 of 76 patients with adrenal insufficiency had celiac disease in a Norwegian study, suggesting that patients with either disorder should be evaluated for the other as well [<a href="#rid30">30,31</a>].</p><p>The genetics and pathogenesis of these disorders are discussed separately. (See  <a class="medical medical_review" href="/d/html/169.html" rel="external">"Pathogenesis of autoimmune adrenal insufficiency"</a>.)</p><p class="headingAnchor" id="H3"><span class="h3">Type 1 (monogenic)</span><span class="headingEndMark"> — </span>Polyglandular autoimmune syndrome type 1, also referred to as the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) syndrome, is a rare autosomal recessive disorder in which females are affected slightly more frequently than males [<a href="#rid17">17-19</a>]. It is most common among Finns, Sardinians, and Iranian Jews; sporadic cases also have been identified elsewhere, including most European countries [<a href="#rid32">32,33</a>]. (See  <a class="medical medical_review" href="/d/html/169.html" rel="external">"Pathogenesis of autoimmune adrenal insufficiency"</a>.)</p><p class="headingAnchor" id="H1925657"><span class="h4">Genetics</span><span class="headingEndMark"> — </span>The classic clinical presentation of APECED is an autosomal recessive disorder caused by mutations in the autoimmune regulator (<em>AIRE</em>) gene on chromosome 21q22.3 [<a href="#rid34">34-36</a>]. The predominant gene mutation differs in different patient populations [<a href="#rid36">36-39</a>]. There is no apparent correlation between specific gene mutations and phenotype. The variable clinical presentation and progression are presumably due to environmental factors and genetic factors other than <em>AIRE</em> gene mutations [<a href="#rid36">36</a>].</p><p>Patients with an atypical presentation have been characterized as nonclassic APECED. Recently, such patients were reported to have an autosomal dominant inheritance, in which dominant-negative mono-allelic mutations in the first zinc finger domain of the <em>AIRE </em>gene result in a later presentation with fewer clinical features [<a href="#rid40">40</a>].</p><p>The <em>AIRE</em> gene product is expressed in the thymus, lymph nodes, pancreas, adrenal cortex, and fetal liver; it appears to be a nuclear transcription factor and induces a variety of tissue-specific antigens in thymic medullary epithelial cells. T-cells that react to these self-antigens are then deleted, resulting in induction of "tolerance" to self-antigens [<a href="#rid41">41</a>]. In the absence of a functional <em>AIRE</em> gene, autoantibodies may be generated [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H1925664"><span class="h4">Classic APECED</span><span class="headingEndMark"> — </span>The clinical diagnosis of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) syndrome is established by the presence of at least two of the following: hypoparathyroidism, chronic mucocutaneous candidiasis, and adrenal insufficiency.</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoparathyroidism or chronic mucocutaneous candidiasis is usually the first manifestation, characteristically appearing during childhood or early adolescence, always by the early twenties  (<a class="graphic graphic_table graphicRef67520" href="/d/graphic/67520.html" rel="external">table 3</a>) [<a href="#rid12">12,17-19</a>]. The hypoparathyroidism may [<a href="#rid43">43,44</a>] or may not [<a href="#rid45">45</a>] occur in association with anti-parathyroid gland antibodies that are directed against the calcium-sensing receptor. (See  <a class="medical medical_review" href="/d/html/840.html" rel="external">"Etiology of hypocalcemia in adults", section on 'Autoimmune'</a>.)</p><p></p><p class="bulletIndent1">The candidiasis almost always involves the mouth, although it may involve just the nail beds or be more extensive  (<a class="graphic graphic_picture graphicRef64895" href="/d/graphic/64895.html" rel="external">picture 1</a>) [<a href="#rid17">17</a>]. It is chronic or recurrent, and it is resistant to conventional therapy (see  <a class="medical medical_review" href="/d/html/2416.html" rel="external">"Overview of Candida infections", section on 'Chronic mucocutaneous candidiasis'</a>). Oral mucous squamous cell carcinoma has been rarely reported in association with the candidiasis of APECED [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adrenal insufficiency usually develops later, at age 10 to 15 years. The antigen targets are adrenal enzymes including P450scc (side-chain cleavage enzyme), P450c17 (17-alpha-hydroxylase), and P450c21 (21-hydroxylase) [<a href="#rid47">47</a>]. The presence of adrenal autoantibodies has a high (92 percent) positive predictive value for development of adrenal insufficiency [<a href="#rid15">15,48</a>]. (See  <a class="medical medical_review" href="/d/html/169.html" rel="external">"Pathogenesis of autoimmune adrenal insufficiency", section on 'Prediction of adrenal insufficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary hypogonadism occurs in approximately 60 percent of patients. (See  <a class="medical medical_review" href="/d/html/7414.html" rel="external">"Autoimmune primary ovarian insufficiency (premature ovarian failure)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malabsorption and other gastrointestinal disorders occur in approximately 25 percent of patients [<a href="#rid49">49,50</a>], of whom 90 percent have autoantibodies to tryptophan hydroxylase, an intestinal antigen. Only one-third of patients without gastrointestinal disorders have these autoantibodies. One report described a patient with severe malabsorption syndrome due to a deficiency of cholecystokinin-producing enteroendocrine cells in the mucosa of the proximal small bowel [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Enamel hypoplasia is also common.</p><p></p><p>In one series of 68 Finnish patients, approximately 50 percent of patients developed the triad of candidiasis, hypoparathyroidism, and adrenal failure [<a href="#rid17">17</a>]. Diabetes mellitus and chronic autoimmune thyroiditis are uncommon. Graves' disease is not associated with this disorder  (<a class="graphic graphic_table graphicRef67520" href="/d/graphic/67520.html" rel="external">table 3</a>).</p><p>In the patient series noted [<a href="#rid17">17</a>], the incidence of various manifestations was different from that reported in other smaller series and reviews of the literature [<a href="#rid17">17</a>]. These differences from previous reports may reflect a variant form of the disorder or more thorough examination of affected patients. As an example, diabetes mellitus was 12 times more prevalent, and manifestations of ectodermal dysplasia, including dental enamel hypoplasia, pitted dystrophy of the nails, keratopathy, and calcified plaques on the tympanic membranes, were present in one-third to two-thirds of the patients. In a report of 62 Finnish and 7 Swedish patients, 17 percent had autoimmune chronic active hepatitis in association with antibodies directed against aromatic L-amino acid decarboxylase [<a href="#rid52">52</a>]. The use of autoantibodies to predict disease manifestations is reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/169.html" rel="external">"Pathogenesis of autoimmune adrenal insufficiency", section on 'Humoral immunity'</a>.)</p><p class="headingAnchor" id="H2136205663"><span class="h4">Nonclassic APECED</span><span class="headingEndMark"> — </span>These patients may present with classic autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) manifestations as described above, but with onset during adulthood, or they may present with polyglandular autoimmune syndrome type 2 or isolated, organ-specific autoimmunity (especially vitiligo and pernicious anemia) [<a href="#rid40">40,53</a>]. In another study of 28 patients, "minor" features appeared first, including urticarial eruption (78.6 percent), intestinal dysfunction (53.6 percent), and enamel hypoplasia (42.9 percent) [<a href="#rid53">53</a>]. The variable clinical presentation and progression are presumably due to environmental factors and genetic factors other than <em>AIRE</em> gene mutations [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H4"><span class="h3">Type 2 (polygenic)</span><span class="headingEndMark"> — </span>Polyglandular autoimmune syndrome type 2 is much more prevalent than type 1 syndrome, and primary adrenal insufficiency is its principal manifestation [<a href="#rid18">18,19,54</a>]. Autoimmune thyroid disease and type 1 diabetes mellitus are also common. Approximately one-half of the cases are familial, with polygenic modes of inheritance. It occurs later than type 1, usually presenting by age 40 years.</p><p>Initial classification of polygenic autoimmune syndromes included subtype 2 (characterized by adrenal insufficiency), type 3 (characterized by autoimmune thyroid disease), and type 4 (those patients who did not fit polyglandular autoimmune syndrome types 1 through 3). Over time, it became clear that types 2 to 4 overlap and are distinct from type 1 [<a href="#rid41">41</a>]. Thus, here we refer to all non-APECED presentations as type 2. Antibodies to steroidogenic enzymes also are present in this disorder and may help to predict the risk of development of additional autoimmune disorders [<a href="#rid42">42,47</a>].</p><p>Autoimmune thyroid disease, usually chronic autoimmune thyroiditis but occasionally Graves' disease, and type 1 diabetes mellitus are also common  (<a class="graphic graphic_table graphicRef69574" href="/d/graphic/69574.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef67520" href="/d/graphic/67520.html" rel="external">table 3</a>). Patients with autoimmune adrenal insufficiency as part of one of the polyglandular autoimmune syndromes are predominately female (70 percent). Approximately one-half of cases are familial, and several modes of inheritance (autosomal recessive, autosomal dominant, and polygenic) have been reported [<a href="#rid12">12,18,19</a>]. Women are affected up to three times more often than men [<a href="#rid54">54</a>]. The age of onset ranges from childhood to late adulthood, with most cases occurring between age 20 and 40 years [<a href="#rid12">12,18,23,54</a>].</p><p class="headingAnchor" id="H1925680"><span class="h4">Affected endocrine organs</span></p><p class="bulletIndent1"><span class="glyph">●</span>Adrenal insufficiency is the initial manifestation in approximately 50 percent of patients, occurs simultaneously with autoimmune thyroid disease or diabetes mellitus in approximately 20 percent, and follows them in approximately 30 percent [<a href="#rid12">12,18,23</a>]. In one series, however, adrenal insufficiency was the initial manifestation in only 19 percent of patients [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary hypogonadism can occur first and, as in polyglandular autoimmune syndrome type 1, ovarian failure is more frequent than testicular failure [<a href="#rid18">18,19,23</a>]. (See  <a class="medical medical_review" href="/d/html/7414.html" rel="external">"Autoimmune primary ovarian insufficiency (premature ovarian failure)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypoparathyroidism does <strong>not</strong> occur in this disorder, and alopecia and pernicious anemia are much less frequent than in the type 1 syndrome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypopituitarism due to autoimmune hypophysitis, preferentially causing ACTH deficiency, can occur alone or in combination with thyrotropin or, rarely, growth hormone deficiency [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/d/html/6636.html" rel="external">"Causes of hypopituitarism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other nonendocrine autoimmune disorders, such as vitiligo, myasthenia gravis, thrombocytopenic purpura, Sjögren's disease, rheumatoid arthritis, and primary antiphospholipid syndrome, occur occasionally [<a href="#rid18">18,19,56</a>], as does serositis with pericardial and/or pleural involvement [<a href="#rid57">57</a>]. Patients with vitiligo, as an example, can have autoantibodies to tyrosinase, an enzyme involved in the synthesis of melanin, tyrosinase-related proteins, or to a melanocyte-specific protein called Pmel17 [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/d/html/4667.html" rel="external">"Clinical manifestations of antiphospholipid syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H5"><span class="h1">INFECTIOUS ADRENALITIS</span><span class="headingEndMark"> — </span>A variety of infectious agents can infect the adrenal gland and lead to adrenal insufficiency.</p><p class="headingAnchor" id="H6"><span class="h2">Tuberculosis</span><span class="headingEndMark"> — </span>Tuberculosis can destroy the adrenal glands. Tuberculous adrenalitis results from hematogenous spread from active infection elsewhere in the body [<a href="#rid59">59</a>]. Extraadrenal tuberculosis is usually evident, but may be clinically latent [<a href="#rid59">59,60</a>]. (See  <a class="medical medical_review" href="/d/html/8024.html" rel="external">"Clinical manifestations, diagnosis, and treatment of miliary tuberculosis", section on 'Clinical manifestations'</a>.)</p><p>Adrenal destruction is gradual, with the medulla being destroyed more often than the cortex, for unknown reasons [<a href="#rid59">59</a>]. Antiadrenal autoantibodies are <strong>not </strong>present in serum [<a href="#rid61">61</a>]. The adrenal glands are usually enlarged by inflammatory cell infiltration of the cortex and granulomas early in the disease; the increase in size can be detected by computed tomography (CT) or magnetic resonance imaging (MRI) [<a href="#rid60">60,62,63</a>]. Caseous nodules and fibrosis then gradually replace the adrenal gland tissue [<a href="#rid60">60</a>], so that after approximately two years, the adrenals become normal or small in size [<a href="#rid60">60,62-64</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Adrenal calcifications can be seen radiographically in 50 percent of patients [<a href="#rid60">60,62,64</a>]. However, the absence of enlarged or calcified adrenal glands does not rule out tuberculosis as the cause of adrenal insufficiency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recovery of normal adrenal function may occur after effective antituberculous therapy [<a href="#rid65">65</a>], but usually does not [<a href="#rid66">66</a>].</p><p></p><p>The adrenal glands may be enlarged in patients with pulmonary tuberculosis even when adrenal function is normal. Adrenal size becomes smaller after successful treatment of the tuberculosis [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Disseminated fungal infections</span><span class="headingEndMark"> — </span>Several species of fungi can involve the adrenal glands and cause adrenal insufficiency. Histoplasmosis [<a href="#rid68">68,69</a>] and paracoccidioidomycosis (South American blastomycosis) [<a href="#rid5">5,70</a>] are important causes of adrenal insufficiency in endemic areas. In contrast, adrenal insufficiency is rare in patients with cryptococcosis, coccidioidomycosis, and North American blastomycosis [<a href="#rid71">71-73</a>]. (See  <a class="medical medical_review" href="/d/html/2455.html" rel="external">"Pathogenesis and clinical manifestations of disseminated histoplasmosis", section on 'Adrenal involvement'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>The adrenal glands are enlarged and may become calcified in all of these disorders.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recovery of adrenal function after prolonged anti-fungal treatment can occur [<a href="#rid69">69</a>].</p><p></p><p class="headingAnchor" id="H8"><span class="h2">HIV infection</span><span class="headingEndMark"> — </span>In the early acquired immunodeficiency syndrome (AIDS) epidemic, the diverse endocrine manifestations of human immunodeficiency virus (HIV) infection, including adrenal insufficiency, were more often a consequence of opportunistic infections, neoplasms, or concomitant systemic illness. The widespread use of potent antiretroviral therapy has led to a decline in the incidence of endocrine complications. (See  <a class="medical medical_review" href="/d/html/3720.html" rel="external">"Pituitary and adrenal gland dysfunction in patients with HIV", section on 'Alterations in adrenal function'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Other infections</span><span class="headingEndMark"> — </span>A few other infections are rare causes of primary adrenal insufficiency. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Syphilis, in which gumma formation and demonstrable spirochetes may be seen [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>African trypanosomiasis, unrelated to its treatment with <a class="drug drug_general" data-topicid="10291" href="/d/drug information/10291.html" rel="external">suramin</a>, which can impair adrenal function when given in higher than the usual therapeutic doses [<a href="#rid74">74</a>]. In another study of 60 patients, five had insufficient cortisol responses to ACTH stimulation on admission, and another five had an abnormal response on discharge; all improved during follow-up evaluation [<a href="#rid75">75</a>].</p><p></p><p class="headingAnchor" id="H10"><span class="h1">HEMORRHAGIC INFARCTION</span><span class="headingEndMark"> — </span>Acute adrenal insufficiency may occur as a result of bilateral adrenal infarction caused by hemorrhage or adrenal vein thrombosis [<a href="#rid76">76-78</a>]. Adrenal hemorrhage has been associated with meningococcemia (Waterhouse-Friderichsen syndrome) [<a href="#rid79">79</a>], but <em>Pseudomonas aeruginosa</em> was the most common pathogen in one report of 51 children dying of sepsis and bilateral adrenal hemorrhage [<a href="#rid80">80</a>]. Waterhouse-Friderichsen syndrome has also been reported with sepsis from <em>Streptococcus pneumoniae</em>, <em>Neisseria gonorrhoeae</em>, <em>Escherichia coli</em>, <em>Haemophilus influenzae</em>, and <em>Staphylococcus aureus</em>. (See  <a class="medical medical_review" href="/d/html/2135.html" rel="external">"Clinical manifestations of Staphylococcus aureus infection in adults"</a>.)</p><p>Adrenal hemorrhage and death have been associated with meningococcemia (Waterhouse-Friderichsen syndrome) [<a href="#rid79">79</a>]. Petechiae are present in approximately 50 to 60 percent of patients [<a href="#rid81">81</a>], so that Waterhouse-Friderichsen syndrome should be considered in a patient with fever and petechiae. Sepsis, bilateral adrenal hemorrhage, and death have also been reported with <em>H. influenzae</em>, <em>E. coli</em>, <em>Mycoplasma pneumoniae</em>, <em>S. pneumoniae</em>, and <em>S. aureus</em> infection, as well as with infective endocarditis, Rocky Mountain spotted fever, murine and epidemic typhus, and viral infections (including cytomegalovirus, parvovirus B19, and Epstein-Barr virus) [<a href="#rid80">80,82,83</a>].</p><p>Bilateral adrenal hemorrhages are present in approximately 1 percent of routine autopsies and, before the availability of CT scanning  (<a class="graphic graphic_diagnosticimage graphicRef63935" href="/d/graphic/63935.html" rel="external">image 1</a>) and MRI, the diagnosis was usually made at autopsy [<a href="#rid76">76,78</a>]. The symptoms and signs include hypotension or shock (&gt;90 percent of patients); abdominal, back, flank, or lower chest pain (86 percent); fever (66 percent); anorexia, nausea, or vomiting (47 percent); confusion or disorientation (42 percent); and abdominal rigidity or rebound (22 percent) [<a href="#rid77">77</a>]. (See <a class="local">'Bilateral adrenal injury'</a> below.)</p><p>Major risk factors for adrenal hemorrhage include anticoagulant drug or heparin therapy (heparin-induced thrombocytopenia resulting in bilateral adrenal hemorrhage) [<a href="#rid84">84</a>], thromboembolic disease, hypercoagulable states such as antiphospholipid syndrome [<a href="#rid85">85,86</a>], physical trauma, the postoperative state, sepsis, and any cause of severe stress [<a href="#rid78">78,87</a>]. In patients treated with anticoagulants, clotting test results are usually within the therapeutic range and spontaneous bleeding elsewhere is not evident [<a href="#rid77">77</a>].</p><p>Evidence of occult hemorrhage, such as a sudden fall in hemoglobin and hematocrit, and progressive hyperkalemia, hyponatremia, and volume contraction should suggest the diagnosis. However, the condition is difficult to recognize clinically and, despite the often dramatic symptoms, the diagnosis is often missed. Without appropriate therapy, shock progresses to coma and death.</p><p>The pathogenesis of adrenal hemorrhage is unclear. Increased adrenal blood flow stimulated by corticotropin (ACTH) secreted in response to stress may play a contributory role [<a href="#rid78">78</a>]. Anticoagulation therapy is implicated in approximately one-third of patients, but adrenal hemorrhage occurs very rarely in patients who are anticoagulated; when it does, it is usually within the first 2 to 12 days of therapy [<a href="#rid76">76,78,84</a>]. A case-control study (23 patients with bilateral massive adrenal hemorrhage and 92 control patients) reported that thrombocytopenia, heparin use, and sepsis were the variables that were most strongly and independently associated with adrenal hemorrhage risk [<a href="#rid87">87</a>].</p><p class="headingAnchor" id="H2111001995"><span class="h1">BILATERAL ADRENAL INJURY</span><span class="headingEndMark"> — </span>Adrenal insufficiency is a potential complication of blunt trauma to the lower torso, including motor vehicle accidents [<a href="#rid88">88</a>]; cases have been recognized in the intensive care setting as a result of admission CT examinations [<a href="#rid89">89</a>].</p><p>Adrenal crisis also can occur as a result of sudden, bilateral adrenal necrosis caused by hemorrhage, emboli, sepsis, or, very rarely, adrenal vein thrombosis after a back injury [<a href="#rid76">76,77,90</a>]. These patients do not have evidence of preexisting adrenal insufficiency. Before CT became widely available, the diagnosis of adrenal hemorrhage was usually made at autopsy [<a href="#rid76">76</a>]. (See <a class="local">'Hemorrhagic infarction'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presenting symptoms </strong>–<strong> </strong>The presenting symptoms and signs of bilateral adrenal hemorrhage (and the frequency with which they occurred in one report) include [<a href="#rid77">77</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypotension or shock (&gt;90 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Abdominal, flank, back, or lower chest pain (86 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Fever (66 percent, presumably a response to inflammation)</p><p class="bulletIndent2"><span class="glyph">•</span>Anorexia, nausea, or vomiting (47 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Neuropsychiatric symptoms such as confusion or disorientation (42 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Abdominal rigidity or rebound tenderness (22 percent)</p><p></p><p class="bulletIndent1">Surprisingly, only approximately one-half of patients have hypotension before shock. The acute onset does not permit enough time for the patient to become hyperpigmented.</p><p></p><p class="bulletIndent1">Evidence of occult hemorrhage, such as a sudden fall in hemoglobin and hematocrit, with progressive hyperkalemia, hyponatremia, and volume contraction, are other signs that should suggest the diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – The major risk factors for adrenal hemorrhage or infarction are anticoagulant therapy or an underlying coagulopathy (see  <a class="medical medical_review" href="/d/html/1305.html" rel="external">"Acquired hemophilia A (and other acquired coagulation factor inhibitors)"</a>), including the antiphospholipid syndrome, and the postoperative state. In patients treated with an anticoagulant, the results of clotting tests are usually within the therapeutic range, and spontaneous bleeding elsewhere is not evident [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1">Because adrenal crisis is difficult to recognize clinically, it must be considered whenever these symptoms develop in a patient with one or more risk factors. Without appropriate therapy, shock progresses to coma and death. If the patient survives, adrenal function may rarely return to normal months later [<a href="#rid78">78</a>].</p><p></p><p class="headingAnchor" id="H11"><span class="h1">METASTATIC DISEASE</span><span class="headingEndMark"> — </span>Infiltration of the adrenal glands by metastatic cancer is common, probably because of their rich sinusoidal blood supply. At autopsy, adrenal metastases are found in 40 to 60 percent of patients with disseminated lung or breast cancer, 30 percent of patients with melanoma, and 14 to 20 percent of patients with stomach or colon cancer, but clinically evident adrenal insufficiency is uncommon [<a href="#rid91">91-93</a>]. Similar findings occur with lymphoma [<a href="#rid94">94,95</a>].</p><p>The apparent low incidence of clinical adrenal insufficiency in patients with malignant disease is due to the fact that most of the adrenal cortex must be destroyed before hypofunction becomes evident [<a href="#rid96">96,97</a>]. In addition, some of the symptoms of adrenal insufficiency may mistakenly be attributed to cancer. Two small studies have suggested that 20 to 35 percent of patients with bilateral adrenal metastases have at least partial adrenal insufficiency and benefit from glucocorticoid replacement therapy [<a href="#rid92">92,93</a>].</p><p class="headingAnchor" id="H12"><span class="h1">ADVERSE EFFECT OF MEDICATIONS</span><span class="headingEndMark"> — </span>A number of drugs are associated with adrenal insufficiency by a variety of mechanisms.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Checkpoint inhibitor immunotherapy</strong> – Administration of antibodies targeting immune checkpoints (cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] and programmed death 1 [PD-1]) for cancer therapy have been associated with endocrinopathies. Hypothyroidism is most common, but primary and secondary adrenal insufficiency have also been reported [<a href="#rid98">98</a>]. These are thought to represent autoimmune/autoinflammatory adverse events. (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Endocrinopathies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhibitors of cortisol biosynthesis</strong> – Several drugs may cause adrenal insufficiency by inhibiting cortisol biosynthesis. They include the anesthetic-sedative drug <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a> [<a href="#rid99">99</a>], the antimycotic drugs <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> and <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> [<a href="#rid100">100,101</a>], <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a> [<a href="#rid102">102</a>], and the antiparasitic drug <a class="drug drug_general" data-topicid="10291" href="/d/drug information/10291.html" rel="external">suramin</a>, which is also being tested for use in treating prostate cancer [<a href="#rid103">103-105</a>]. These drugs usually do not cause clinically important adrenal insufficiency in patients with normal hypothalamic-pituitary-adrenal function because enzyme inhibition is incomplete and increased corticotropin (ACTH) secretion overrides the pharmacologic blockade. However, patients with limited pituitary or adrenal reserve may develop symptomatic adrenal insufficiency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs that accelerate metabolism of cortisol</strong> – There are drugs that accelerate the metabolism of cortisol and most synthetic glucocorticoids by inducing hepatic mixed-function oxygenase enzymes. They include <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> [<a href="#rid106">106,107</a>], barbiturates [<a href="#rid106">106</a>], and <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> [<a href="#rid106">106,108,109</a>]. These drugs, therefore, can cause adrenal insufficiency in patients with limited pituitary or adrenal reserve and those with adrenal insufficiency who are receiving glucocorticoid therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mitotane</strong> – The adrenocorticolytic drug <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a> is used to treat adrenal tumors and to diminish cortisol synthesis in refractory Cushing syndrome. It also accelerates the metabolism of halogenated synthetic steroids such as <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> and <a class="drug drug_general" data-topicid="8455" href="/d/drug information/8455.html" rel="external">fludrocortisone</a> [<a href="#rid110">110</a>] and can provoke adrenal insufficiency in patients with adrenal carcinoma who are receiving steroids of this type. (See  <a class="medical medical_review" href="/d/html/165.html" rel="external">"Treatment of adrenocortical carcinoma", section on 'Adrenal insufficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs that suppress corticotropin-releasing hormone (CRH) or ACTH production</strong> – This includes glucocorticoids, <a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">megestrol acetate</a> or opioids, or drugs that potentiate glucocorticoid effects by decreasing its metabolism (eg, <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a>), are discussed under causes of central (ie, secondary or tertiary) adrenal insufficiency. (See  <a class="medical medical_review" href="/d/html/173.html" rel="external">"Causes of secondary and tertiary adrenal insufficiency in adults"</a>.)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary adrenal insufficiency</strong> – Adrenal insufficiency is a rare disorder, occurring in up to 144 people per million population. Autoimmune adrenalitis is responsible for 70 to 90 percent, with the remainder being caused by other infectious diseases, replacement by metastatic cancer or lymphoma, adrenal hemorrhage or infarction, or drugs. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autoimmune causes</strong> – Autoimmune adrenalitis involves destruction of the cortex by both humoral and cell-mediated immune mechanisms. Antibodies that react with several steroidogenic enzymes (most often 21-hydroxylase) and all three zones of the adrenal cortex are present in the serum in up to 86 percent of patients. (See <a class="local">'Autoimmune adrenalitis'</a> above.)</p><p></p><p class="bulletIndent1">Up to 50 percent of patients with autoimmune adrenalitis have additional autoimmune disorders; however, adrenal insufficiency is rarely found in patients who present with other autoimmune diseases. (See <a class="local">'Polyglandular autoimmune syndromes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Polyglandular autoimmune syndrome type 1</strong> – Polyglandular autoimmune syndrome type 1 is a rare autosomal recessive disorder caused by mutations in the autoimmune regulator (<em>AIRE</em>) gene, which may be important in the selection and generation of regulatory T cells. Hypoparathyroidism or chronic mucocutaneous candidiasis usually appears during childhood or early adolescence, followed by adrenal insufficiency and potentially by other autoimmune diseases. (See <a class="local">'Type 1 (monogenic)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Polyglandular autoimmune syndrome type 2</strong> – Polyglandular autoimmune syndrome type 2 is much more prevalent than type 1 syndrome. Primary adrenal insufficiency is its principal manifestation, but autoimmune thyroid disease and type 1 diabetes mellitus are also common. Approximately one-half of the cases are familial, with polygenic modes of inheritance. It occurs later than type 1, usually presenting by age 40 years. (See <a class="local">'Type 2 (polygenic)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infectious causes</strong> –<strong> </strong>Infectious causes of adrenal insufficiency include tuberculosis, fungal infections, cytomegalovirus and Mycobacterium avium-intracellulare (usually in the context of HIV infection), syphilis, and African trypanosomiasis. (See <a class="local">'Infectious adrenalitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bilateral adrenal hemorrhage</strong> – Bilateral adrenal hemorrhage can inhibit adrenal function. This usually occurs in specific settings (see <a class="local">'Hemorrhagic infarction'</a> above and <a class="local">'Bilateral adrenal injury'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Disseminated infection (meningococcus, <em>Pseudomonas aeruginosa</em>, <em>Streptococcus</em> <em>pneumoniae</em>, <em>Neisseria gonorrhoeae</em>, <em>Escherichia coli</em>, <em>Haemophilus influenzae</em>, and <em>Staphylococcus aureus</em>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clotting abnormalities (anticoagulant drug or heparin therapy or coagulopathy, thromboembolic disease, hypercoagulable states such as antiphospholipid syndrome).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other associations include physical trauma, the postoperative state, sepsis, and severe stress.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metastatic disease</strong> –<strong> </strong>Metastatic disease with replacement of the cortex of both adrenal glands is a rare cause of adrenal insufficiency. (See <a class="local">'Metastatic disease'</a> above.)</p><p></p><p class="bulletIndent1">This is most commonly associated with lung, breast, stomach, or colon cancer, melanoma, and lymphoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs</strong> – Drugs are an important cause of primary adrenal insufficiency. (See <a class="local">'Adverse effect of medications'</a> above.)</p><p></p><p class="bulletIndent1">These include drugs that inhibit cortisol biosynthesis, such as <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a>, <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a>, <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>, <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a>, <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a>, and <a class="drug drug_general" data-topicid="10291" href="/d/drug information/10291.html" rel="external">suramin</a>.</p><p></p><p class="bulletIndent1">Other drugs accelerate the metabolism of cortisol and most synthetic glucocorticoids by inducing hepatic mixed-function oxygenase enzymes (eg, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, barbiturates, <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a>, and <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>). These can cause adrenal insufficiency in patients with limited adrenal reserve who cannot compensate for the accelerated cortisol metabolism.</p><p></p><p class="headingAnchor" id="H3406933357"><span class="h1">DISCLOSURE</span><span class="headingEndMark"> — </span>The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Addison T. On the Constitutional and Local Effects of Disease of the Suprarenal Capsules, Highley, London 1855.</li><li><a class="nounderline abstract_t">Irvine WJ, Barnes EW. Adrenocortical insufficiency. Clin Endocrinol Metab 1972; 1:549.</a></li><li><a class="nounderline abstract_t">Zelissen PM, Bast EJ, Croughs RJ. Associated autoimmunity in Addison's disease. J Autoimmun 1995; 8:121.</a></li><li><a class="nounderline abstract_t">Kasperlik-Zaluska AA, Migdalska B, Czarnocka B, et al. Association of Addison's disease with autoimmune disorders--a long-term observation of 180 patients. Postgrad Med J 1991; 67:984.</a></li><li><a class="nounderline abstract_t">Moreira AC, Martinez R, Castro M, Elias LL. Adrenocortical dysfunction in paracoccidioidomycosis: comparison between plasma beta-lipotrophin/adrenocorticotrophin levels and adrenocortical tests. Clin Endocrinol (Oxf) 1992; 36:545.</a></li><li><a class="nounderline abstract_t">Chabre O, Goichot B, Zenaty D, Bertherat J. Group 1. Epidemiology of primary and secondary adrenal insufficiency: Prevalence and incidence, acute adrenal insufficiency, long-term morbidity and mortality. Ann Endocrinol (Paris) 2017; 78:490.</a></li><li><a class="nounderline abstract_t">Nomura K, Demura H, Saruta T. Addison's disease in Japan: characteristics and changes revealed in a nationwide survey. Intern Med 1994; 33:602.</a></li><li><a class="nounderline abstract_t">Willis AC, Vince FP. The prevalence of Addison's disease in Coventry, UK. Postgrad Med J 1997; 73:286.</a></li><li><a class="nounderline abstract_t">Laureti S, Vecchi L, Santeusanio F, Falorni A. Is the prevalence of Addison's disease underestimated? J Clin Endocrinol Metab 1999; 84:1762.</a></li><li><a class="nounderline abstract_t">Erichsen MM, Løvås K, Skinningsrud B, et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab 2009; 94:4882.</a></li><li><a class="nounderline abstract_t">Husebye ES, Løvås K. Immunology of Addison's disease and premature ovarian failure. Endocrinol Metab Clin North Am 2009; 38:389.</a></li><li><a class="nounderline abstract_t">Spinner MW, Blizzard RM, Childs B. Clinical and genetic heterogeneity in idiopathic Addison's disease and hypoparathyroidism. J Clin Endocrinol Metab 1968; 28:795.</a></li><li><a class="nounderline abstract_t">Betterle C, Scalici C, Presotto F, et al. The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. J Endocrinol 1988; 117:467.</a></li><li><a class="nounderline abstract_t">Saenger P, Levine LS, Irvine WJ, et al. Progressive adrenal failure in polyglandular autoimmune disease. J Clin Endocrinol Metab 1982; 54:863.</a></li><li><a class="nounderline abstract_t">Ahonen P, Miettinen A, Perheentupa J. Adrenal and steroidal cell antibodies in patients with autoimmune polyglandular disease type I and risk of adrenocortical and ovarian failure. J Clin Endocrinol Metab 1987; 64:494.</a></li><li><a class="nounderline abstract_t">Baker PR, Nanduri P, Gottlieb PA, et al. Predicting the onset of Addison's disease: ACTH, renin, cortisol and 21-hydroxylase autoantibodies. Clin Endocrinol (Oxf) 2012; 76:617.</a></li><li><a class="nounderline abstract_t">Ahonen P, Myllärniemi S, Sipilä I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990; 322:1829.</a></li><li><a class="nounderline abstract_t">Neufeld M, Maclaren NK, Blizzard RM. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine (Baltimore) 1981; 60:355.</a></li><li><a class="nounderline abstract_t">Trence DL, Morley JE, Handwerger BS. Polyglandular autoimmune syndromes. Am J Med 1984; 77:107.</a></li><li><a class="nounderline abstract_t">Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med 2004; 350:2068.</a></li><li><a class="nounderline abstract_t">Blizzard RM, Chee D, Davis W. The incidence of adrenal and other antibodies in the sera of patients with idiopathic adrenal insufficiency (Addison's disease). Clin Exp Immunol 1967; 2:19.</a></li><li><a class="nounderline abstract_t">McHardy-Young S, Lessof MH, Maisey MN. Serum TSH and thyroid antibody studies in Addison's disease. Clin Endocrinol (Oxf) 1972; 1:45.</a></li><li><a class="nounderline abstract_t">Nerup J. Addison's disease--clinical studies. A report fo 108 cases. Acta Endocrinol (Copenh) 1974; 76:127.</a></li><li><a class="nounderline abstract_t">Myhre AG, Undlien DE, Løvås K, et al. Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features. J Clin Endocrinol Metab 2002; 87:618.</a></li><li><a class="nounderline abstract_t">Brewer, KW, Parziale, et al. Screening patients with insulin-dependent diabetes mellitus for adrenal insufficiency (letter). New Engl J Med 1997; 337:202.</a></li><li><a class="nounderline abstract_t">Marks SD, Girgis R, Couch RM. Screening for adrenal antibodies in children with type 1 diabetes and autoimmune thyroid disease. Diabetes Care 2003; 26:3187.</a></li><li><a class="nounderline abstract_t">Yu L, Brewer KW, Gates S, et al. DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease. J Clin Endocrinol Metab 1999; 84:328.</a></li><li><a class="nounderline abstract_t">Triolo TM, Baschal EE, Armstrong TK, et al. Homozygosity of the polymorphism MICA5.1 identifies extreme risk of progression to overt adrenal insufficiency among 21-hydroxylase antibody-positive patients with type 1 diabetes. J Clin Endocrinol Metab 2009; 94:4517.</a></li><li><a class="nounderline abstract_t">Barker JM, Ide A, Hostetler C, et al. Endocrine and immunogenetic testing in individuals with type 1 diabetes and 21-hydroxylase autoantibodies: Addison's disease in a high-risk population. J Clin Endocrinol Metab 2005; 90:128.</a></li><li><a class="nounderline abstract_t">Elfström P, Montgomery SM, Kämpe O, et al. Risk of primary adrenal insufficiency in patients with celiac disease. J Clin Endocrinol Metab 2007; 92:3595.</a></li><li><a class="nounderline abstract_t">Myhre AG, Aarsetøy H, Undlien DE, et al. High frequency of coeliac disease among patients with autoimmune adrenocortical failure. Scand J Gastroenterol 2003; 38:511.</a></li><li><a class="nounderline abstract_t">Ferre EM, Rose SR, Rosenzweig SD, et al. Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight 2016; 1.</a></li><li><a class="nounderline abstract_t">Orlova EM, Sozaeva LS, Kareva MA, et al. Expanding the Phenotypic and Genotypic Landscape of Autoimmune Polyendocrine Syndrome Type 1. J Clin Endocrinol Metab 2017; 102:3546.</a></li><li><a class="nounderline abstract_t">Scott HS, Heino M, Peterson P, et al. Common mutations in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients of different origins. Mol Endocrinol 1998; 12:1112.</a></li><li><a class="nounderline abstract_t">Nagamine K, Peterson P, Scott HS, et al. Positional cloning of the APECED gene. Nat Genet 1997; 17:393.</a></li><li><a class="nounderline abstract_t">Heino M, Scott HS, Chen Q, et al. Mutation analyses of North American APS-1 patients. Hum Mutat 1999; 13:69.</a></li><li><a class="nounderline abstract_t">Meloni A, Perniola R, Faà V, et al. Delineation of the molecular defects in the AIRE gene in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients from Southern Italy. J Clin Endocrinol Metab 2002; 87:841.</a></li><li><a class="nounderline abstract_t">Finnish-German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 1997; 17:399.</a></li><li><a class="nounderline abstract_t">Rosatelli MC, Meloni A, Meloni A, et al. A common mutation in Sardinian autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients. Hum Genet 1998; 103:428.</a></li><li><a class="nounderline abstract_t">Oftedal BE, Hellesen A, Erichsen MM, et al. Dominant Mutations in the Autoimmune Regulator AIRE Are Associated with Common Organ-Specific Autoimmune Diseases. Immunity 2015; 42:1185.</a></li><li><a class="nounderline abstract_t">Taniguchi RT, Anderson MS. The role of Aire in clonal selection. Immunol Cell Biol 2011; 89:40.</a></li><li><a class="nounderline abstract_t">Husebye ES, Anderson MS, Kämpe O. Autoimmune Polyendocrine Syndromes. N Engl J Med 2018; 378:1132.</a></li><li><a class="nounderline abstract_t">Li Y, Song YH, Rais N, et al. Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism. J Clin Invest 1996; 97:910.</a></li><li><a class="nounderline abstract_t">Kifor O, McElduff A, LeBoff MS, et al. Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism. J Clin Endocrinol Metab 2004; 89:548.</a></li><li><a class="nounderline abstract_t">Söderbergh A, Myhre AG, Ekwall O, et al. Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 2004; 89:557.</a></li><li><a class="nounderline abstract_t">Böckle BC, Wilhelm M, Müller H, et al. Oral mucous squamous cell carcinoma-an anticipated consequence of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). J Am Acad Dermatol 2010; 62:864.</a></li><li><a class="nounderline abstract_t">Chen S, Sawicka J, Betterle C, et al. Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison's disease, and premature ovarian failure. J Clin Endocrinol Metab 1996; 81:1871.</a></li><li><a class="nounderline abstract_t">Gylling M, Tuomi T, Björses P, et al. ss-cell autoantibodies, human leukocyte antigen II alleles, and type 1 diabetes in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab 2000; 85:4434.</a></li><li><a class="nounderline abstract_t">Betterle C, Greggio NA, Volpato M. Clinical review 93: Autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab 1998; 83:1049.</a></li><li><a class="nounderline abstract_t">Ekwall O, Hedstrand H, Grimelius L, et al. Identification of tryptophan hydroxylase as an intestinal autoantigen. Lancet 1998; 352:279.</a></li><li><a class="nounderline abstract_t">Högenauer C, Meyer RL, Netto GJ, et al. Malabsorption due to cholecystokinin deficiency in a patient with autoimmune polyglandular syndrome type I. N Engl J Med 2001; 344:270.</a></li><li><a class="nounderline abstract_t">Husebye ES, Gebre-Medhin G, Tuomi T, et al. Autoantibodies against aromatic L-amino acid decarboxylase in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 1997; 82:147.</a></li><li><a class="nounderline abstract_t">Guo CJ, Leung PSC, Zhang W, et al. The immunobiology and clinical features of type 1 autoimmune polyglandular syndrome (APS-1). Autoimmun Rev 2018; 17:78.</a></li><li><a class="nounderline abstract_t">Dittmar M, Kahaly GJ. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab 2003; 88:2983.</a></li><li><a class="nounderline abstract_t">Ward L, Paquette J, Seidman E, et al. Severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in an adolescent girl with a novel AIRE mutation: response to immunosuppressive therapy. J Clin Endocrinol Metab 1999; 84:844.</a></li><li><a class="nounderline abstract_t">Asherson RA, Hughes GR. Recurrent deep vein thrombosis and Addison's disease in "primary" antiphospholipid syndrome. J Rheumatol 1989; 16:378.</a></li><li><a class="nounderline abstract_t">Tucker WS Jr, Niblack GD, McLean RH, et al. Serositis with autoimmune endocrinopathy: clinical and immunogenetic features. Medicine (Baltimore) 1987; 66:138.</a></li><li><a class="nounderline abstract_t">Kemp EH, Gawkrodger DJ, Watson PF, Weetman AP. Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA). Clin Exp Immunol 1998; 114:333.</a></li><li><a class="nounderline abstract_t">Guttman PH. Addison's disease. A statistical analysis of five hundred and sixty-six cases and a study of the pathology. Arch Pathol 1930; 10:742.</a></li><li><a class="nounderline abstract_t">Vita JA, Silverberg SJ, Goland RS, et al. Clinical clues to the cause of Addison's disease. Am J Med 1985; 78:461.</a></li><li><a class="nounderline abstract_t">Laureti S, Aubourg P, Calcinaro F, et al. Etiological diagnosis of primary adrenal insufficiency using an original flowchart of immune and biochemical markers. J Clin Endocrinol Metab 1998; 83:3163.</a></li><li><a class="nounderline abstract_t">Sun ZH, Nomura K, Toraya S, et al. Clinical significance of adrenal computed tomography in Addison's disease. Endocrinol Jpn 1992; 39:563.</a></li><li><a class="nounderline abstract_t">Villabona CM, Sahun M, Ricart W, et al. Tuberculous Addison's disease. Utility of CT in diagnosis and follow-up. Eur J Radiol 1993; 17:210.</a></li><li><a class="nounderline abstract_t">Guo YK, Yang ZG, Li Y, et al. Addison's disease due to adrenal tuberculosis: contrast-enhanced CT features and clinical duration correlation. Eur J Radiol 2007; 62:126.</a></li><li><a class="nounderline abstract_t">Penrice J, Nussey SS. Recovery of adrenocortical function following treatment of tuberculous Addison's disease. Postgrad Med J 1992; 68:204.</a></li><li><a class="nounderline abstract_t">Bhatia E, Jain SK, Gupta RK, Pandey R. Tuberculous Addison's disease: lack of normalization of adrenocortical function after anti-tuberculous chemotherapy. Clin Endocrinol (Oxf) 1998; 48:355.</a></li><li><a class="nounderline abstract_t">Gülmez I, Keleştimur F, Durak AC, Ozesmi M. Changes in the size of adrenal glands in acute pulmonary tuberculosis with therapy. Endocr J 1996; 43:573.</a></li><li><a class="nounderline abstract_t">Sarosi GA, Voth DW, Dahl BA, et al. Disseminated histoplasmosis: results of long-term follow-up. A center for disease control cooperative mycoses study. Ann Intern Med 1971; 75:511.</a></li><li><a class="nounderline abstract_t">Washburn RG, Bennett JE. Reversal of adrenal glucocorticoid dysfunction in a patient with disseminated histoplasmosis. Ann Intern Med 1989; 110:86.</a></li><li><a class="nounderline abstract_t">Abad A, Gomez I, Velez P, Restrepo A. Adrenal function in paracoccidioidomycosis: a prospective study in patients before and after ketoconazole therapy. Infection 1986; 14:22.</a></li><li><a class="nounderline abstract_t">Walker BF, Gunthel CJ, Bryan JA, et al. Disseminated cryptococcosis in an apparently normal host presenting as primary adrenal insufficiency: diagnosis by fine needle aspiration. Am J Med 1989; 86:715.</a></li><li><a class="nounderline abstract_t">MALONEY PJ. Addison's disease due to chronic disseminated coccidioidomycosis. AMA Arch Intern Med 1952; 90:869.</a></li><li><a class="nounderline abstract_t">ABERNATHY RS, MELBY JC. Addison's disease in North American blastomycosis. N Engl J Med 1962; 266:552.</a></li><li><a class="nounderline abstract_t">Heppner C, Petzke F, Arlt W, et al. Adrenocortical insufficiency in Rhodesian sleeping sickness is not attributable to suramin. Trans R Soc Trop Med Hyg 1995; 89:65.</a></li><li><a class="nounderline abstract_t">Blum JA, Schmid C, Hatz C, et al. Sleeping glands? - The role of endocrine disorders in sleeping sickness (T.b. gambiense Human African Trypanosomiasis). Acta Trop 2007; 104:16.</a></li><li><a class="nounderline abstract_t">Xarli VP, Steele AA, Davis PJ, et al. Adrenal hemorrhage in the adult. Medicine (Baltimore) 1978; 57:211.</a></li><li><a class="nounderline abstract_t">Rao RH, Vagnucci AH, Amico JA. Bilateral massive adrenal hemorrhage: early recognition and treatment. Ann Intern Med 1989; 110:227.</a></li><li><a class="nounderline abstract_t">Streeten DHP. Adrenal hemorrhage. Endocrinologist 1996; 6:277.</a></li><li><a class="nounderline abstract_t">Migeon CJ, Kenny FM, Hung W, Voorhess ML. Study of adrenal function in children with meningitis. Pediatrics 1967; 40:163.</a></li><li><a class="nounderline abstract_t">MARGARETTEN W, NAKAI H, LANDING BH. Septicemic adrenal hemorrhage. Am J Dis Child 1963; 105:346.</a></li><li><a class="nounderline abstract_t">Varon J, Chen K, Sternbach GL. Rupert Waterhouse and Carl Friderichsen: adrenal apoplexy. J Emerg Med 1998; 16:643.</a></li><li><a class="nounderline abstract_t">Adem PV, Montgomery CP, Husain AN, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med 2005; 353:1245.</a></li><li><a class="nounderline abstract_t">Tormos LM, Schandl CA. The significance of adrenal hemorrhage: undiagnosed Waterhouse-Friderichsen syndrome, a case series. J Forensic Sci 2013; 58:1071.</a></li><li><a class="nounderline abstract_t">Rosenberger LH, Smith PW, Sawyer RG, et al. Bilateral adrenal hemorrhage: the unrecognized cause of hemodynamic collapse associated with heparin-induced thrombocytopenia. Crit Care Med 2011; 39:833.</a></li><li><a class="nounderline abstract_t">Caron P, Chabannier MH, Cambus JP, et al. Definitive adrenal insufficiency due to bilateral adrenal hemorrhage and primary antiphospholipid syndrome. J Clin Endocrinol Metab 1998; 83:1437.</a></li><li><a class="nounderline abstract_t">Espinosa G, Santos E, Cervera R, et al. Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients. Medicine (Baltimore) 2003; 82:106.</a></li><li><a class="nounderline abstract_t">Kovacs KA, Lam YM, Pater JL. Bilateral massive adrenal hemorrhage. Assessment of putative risk factors by the case-control method. Medicine (Baltimore) 2001; 80:45.</a></li><li><a class="nounderline abstract_t">Lehrberg A, Kharbutli B. Isolated unilateral adrenal gland hemorrhage following motor vehicle collision: a case report and review of the literature. J Med Case Rep 2017; 11:358.</a></li><li><a class="nounderline abstract_t">Castaldo ET, Guillamondegui OD, Greco JA 3rd, et al. Are adrenal injuries predictive of adrenal insufficiency in patients sustaining blunt trauma? Am Surg 2008; 74:262.</a></li><li><a class="nounderline abstract_t">Warkentin TE, Safyan EL, Linkins LA. Heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages. N Engl J Med 2015; 372:492.</a></li><li><a class="nounderline abstract_t">Cedermark BJ, Blumenson LE, Pickren JW, et al. Ths significance of metastases to the adrenal glands in adenocarcinoma of the colon and rectum. Surg Gynecol Obstet 1977; 144:537.</a></li><li><a class="nounderline abstract_t">Redman BG, Pazdur R, Zingas AP, Loredo R. Prospective evaluation of adrenal insufficiency in patients with adrenal metastasis. Cancer 1987; 60:103.</a></li><li><a class="nounderline abstract_t">Seidenwurm DJ, Elmer EB, Kaplan LM, et al. Metastases to the adrenal glands and the development of Addison's disease. Cancer 1984; 54:552.</a></li><li><a class="nounderline abstract_t">Serrano S, Tejedor L, Garcia B, et al. Addisonian crisis as the presenting feature of bilateral primary adrenal lymphoma. Cancer 1993; 71:4030.</a></li><li><a class="nounderline abstract_t">Huminer D, Garty M, Lapidot M, et al. Lymphoma presenting with adrenal insufficiency. Adrenal enlargement on computed tomographic scanning as a clue to diagnosis. Am J Med 1988; 84:169.</a></li><li><a class="nounderline abstract_t">Barker NW. The pathologic anatomy in twenty-eight cases of Addison's disease. Arch Pathol 1929; 8:432.</a></li><li><a class="nounderline abstract_t">Cedermark BJ, Sjöberg HE. The clinical significance of metastases to the adrenal glands. Surg Gynecol Obstet 1981; 152:607.</a></li><li><a class="nounderline abstract_t">Chang LS, Barroso-Sousa R, Tolaney SM, et al. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocr Rev 2019; 40:17.</a></li><li><a class="nounderline abstract_t">Jabre P, Combes X, Lapostolle F, et al. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet 2009; 374:293.</a></li><li><a class="nounderline abstract_t">Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987; 317:812.</a></li><li><a class="nounderline abstract_t">Riedl M, Maier C, Zettinig G, et al. Long term control of hypercortisolism with fluconazole: case report and in vitro studies. Eur J Endocrinol 2006; 154:519.</a></li><li><a class="nounderline abstract_t">LIDDLE GW, ISLAND D, LANCE EM, HARRIS AP. Alterations of adrenal steroid patterns in man resulting from treatment with a chemical inhibitor of 11 beta-hydroxylation. J Clin Endocrinol Metab 1958; 18:906.</a></li><li><a class="nounderline abstract_t">Ashby H, DiMattina M, Linehan WM, et al. The inhibition of human adrenal steroidogenic enzyme activities by suramin. J Clin Endocrinol Metab 1989; 68:505.</a></li><li><a class="nounderline abstract_t">Stein CA, Saville W, Yarchoan R, et al. Suramin and function of the adrenal cortex. Ann Intern Med 1986; 104:286.</a></li><li><a class="nounderline abstract_t">Kobayashi K, Weiss RE, Vogelzang NJ, et al. Mineralocorticoid insufficiency due to suramin therapy. Cancer 1996; 78:2411.</a></li><li><a class="nounderline abstract_t">Elias AN, Gwinup G. Effects of some clinically encountered drugs on steroid synthesis and degradation. Metabolism 1980; 29:582.</a></li><li><a class="nounderline abstract_t">Keilholz U, Guthrie GP Jr. Adverse effect of phenytoin on mineralocorticoid replacement with fludrocortisone in adrenal insufficiency. Am J Med Sci 1986; 291:280.</a></li><li><a class="nounderline abstract_t">Kyriazopoulou V, Parparousi O, Vagenakis AG. Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy. J Clin Endocrinol Metab 1984; 59:1204.</a></li><li><a class="nounderline abstract_t">Ediger SK, Isley WL. Rifampicin-induced adrenal insufficiency in the acquired immunodeficiency syndrome: difficulties in diagnosis and treatment. Postgrad Med J 1988; 64:405.</a></li><li><a class="nounderline abstract_t">Robinson BG, Hales IB, Henniker AJ, et al. The effect of o,p'-DDD on adrenal steroid replacement therapy requirements. Clin Endocrinol (Oxf) 1987; 27:437.</a></li></ol></div><div id="topicVersionRevision">Topic 166 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Addison T. On the Constitutional and Local Effects of Disease of the Suprarenal Capsules, Highley, London 1855.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Adrenocortical insufficiency</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7734032" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Associated autoimmunity in Addison's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1775423" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Association of Addison's disease with autoimmune disorders--a long-term observation of 180 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1330381" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Adrenocortical dysfunction in paracoccidioidomycosis: comparison between plasma beta-lipotrophin/adrenocorticotrophin levels and adrenocortical tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29174931" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Group 1. Epidemiology of primary and secondary adrenal insufficiency: Prevalence and incidence, acute adrenal insufficiency, long-term morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7827375" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Addison's disease in Japan: characteristics and changes revealed in a nationwide survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9196701" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The prevalence of Addison's disease in Coventry, UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10323417" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Is the prevalence of Addison's disease underestimated?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19858318" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19328418" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Immunology of Addison's disease and premature ovarian failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5656437" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical and genetic heterogeneity in idiopathic Addison's disease and hypoparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3392502" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The natural history of adrenal function in autoimmune patients with adrenal autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6277984" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Progressive adrenal failure in polyglandular autoimmune disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3818889" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Adrenal and steroidal cell antibodies in patients with autoimmune polyglandular disease type I and risk of adrenocortical and ovarian failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22066755" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Predicting the onset of Addison's disease: ACTH, renin, cortisol and 21-hydroxylase autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2348835" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7024719" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6377888" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Polyglandular autoimmune syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15141045" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Autoimmune polyendocrine syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6030795" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The incidence of adrenal and other antibodies in the sera of patients with idiopathic adrenal insufficiency (Addison's disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4664289" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Serum TSH and thyroid antibody studies in Addison's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4406578" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Addison's disease--clinical studies. A report fo 108 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11836294" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9221352" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Screening patients with insulin-dependent diabetes mellitus for adrenal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14578262" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Screening for adrenal antibodies in children with type 1 diabetes and autoimmune thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9920103" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19820007" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Homozygosity of the polymorphism MICA5.1 identifies extreme risk of progression to overt adrenal insufficiency among 21-hydroxylase antibody-positive patients with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15483092" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Endocrine and immunogenetic testing in individuals with type 1 diabetes and 21-hydroxylase autoantibodies: Addison's disease in a high-risk population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17595243" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Risk of primary adrenal insufficiency in patients with celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12795461" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : High frequency of coeliac disease among patients with autoimmune adrenocortical failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27588307" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28911151" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Expanding the Phenotypic and Genotypic Landscape of Autoimmune Polyendocrine Syndrome Type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9717837" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Common mutations in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients of different origins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9398839" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Positional cloning of the APECED gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9888391" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Mutation analyses of North American APS-1 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11836330" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Delineation of the molecular defects in the AIRE gene in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients from Southern Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9398840" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9856486" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A common mutation in Sardinian autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26084028" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Dominant Mutations in the Autoimmune Regulator AIRE Are Associated with Common Organ-Specific Autoimmune Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21079643" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The role of Aire in clonal selection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29562162" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Autoimmune Polyendocrine Syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8613543" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14764760" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14764761" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20304522" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Oral mucous squamous cell carcinoma-an anticipated consequence of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8626850" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison's disease, and premature ovarian failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11134089" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : ss-cell autoantibodies, human leukocyte antigen II alleles, and type 1 diabetes in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9543115" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clinical review 93: Autoimmune polyglandular syndrome type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9690408" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Identification of tryptophan hydroxylase as an intestinal autoantigen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11172154" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Malabsorption due to cholecystokinin deficiency in a patient with autoimmune polyglandular syndrome type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8989249" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Autoantibodies against aromatic L-amino acid decarboxylase in autoimmune polyendocrine syndrome type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29108822" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The immunobiology and clinical features of type 1 autoimmune polyglandular syndrome (APS-1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12843130" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10084559" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in an adolescent girl with a novel AIRE mutation: response to immunosuppressive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2498514" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Recurrent deep vein thrombosis and Addison's disease in "primary" antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3493414" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Serositis with autoimmune endocrinopathy: clinical and immunogenetic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9844040" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Addison's disease. A statistical analysis of five hundred and sixty-six cases and a study of the pathology</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3976705" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Clinical clues to the cause of Addison's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9745420" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Etiological diagnosis of primary adrenal insufficiency using an original flowchart of immune and biochemical markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1294374" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Clinical significance of adrenal computed tomography in Addison's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8293751" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Tuberculous Addison's disease. Utility of CT in diagnosis and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17182208" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Addison's disease due to adrenal tuberculosis: contrast-enhanced CT features and clinical duration correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1589379" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Recovery of adrenocortical function following treatment of tuberculous Addison's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9578827" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Tuberculous Addison's disease: lack of normalization of adrenocortical function after anti-tuberculous chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8980899" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Changes in the size of adrenal glands in acute pulmonary tuberculosis with therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5094067" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Disseminated histoplasmosis: results of long-term follow-up. A center for disease control cooperative mycoses study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2908832" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Reversal of adrenal glucocorticoid dysfunction in a patient with disseminated histoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3007365" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Adrenal function in paracoccidioidomycosis: a prospective study in patients before and after ketoconazole therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2658577" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Disseminated cryptococcosis in an apparently normal host presenting as primary adrenal insufficiency: diagnosis by fine needle aspiration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12996113" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Addison's disease due to chronic disseminated coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13858940" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Addison's disease in North American blastomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7747311" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Adrenocortical insufficiency in Rhodesian sleeping sickness is not attributable to suramin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17767911" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Sleeping glands? - The role of endocrine disorders in sleeping sickness (T.b. gambiense Human African Trypanosomiasis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/205758" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Adrenal hemorrhage in the adult.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2643380" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Bilateral massive adrenal hemorrhage: early recognition and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Adrenal hemorrhage</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5006579" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Study of adrenal function in children with meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13932989" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Septicemic adrenal hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9696186" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Rupert Waterhouse and Carl Friderichsen: adrenal apoplexy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16177250" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23458363" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The significance of adrenal hemorrhage: undiagnosed Waterhouse-Friderichsen syndrome, a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21242799" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Bilateral adrenal hemorrhage: the unrecognized cause of hemodynamic collapse associated with heparin-induced thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9589635" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Definitive adrenal insufficiency due to bilateral adrenal hemorrhage and primary antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12640187" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11204502" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Bilateral massive adrenal hemorrhage. Assessment of putative risk factors by the case-control method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29277157" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Isolated unilateral adrenal gland hemorrhage following motor vehicle collision: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18376696" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Are adrenal injuries predictive of adrenal insufficiency in patients sustaining blunt trauma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25629757" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/847609" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Ths significance of metastases to the adrenal glands in adenocarcinoma of the colon and rectum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3581024" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Prospective evaluation of adrenal insufficiency in patients with adrenal metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6733685" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Metastases to the adrenal glands and the development of Addison's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8508368" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Addisonian crisis as the presenting feature of bilateral primary adrenal lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3276182" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Lymphoma presenting with adrenal insufficiency. Adrenal enlargement on computed tomographic scanning as a clue to diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : The pathologic anatomy in twenty-eight cases of Addison's disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6261412" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : The clinical significance of metastases to the adrenal glands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30184160" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19573904" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3306384" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The use of ketoconazole as an inhibitor of steroid production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16556713" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Long term control of hypercortisolism with fluconazole: case report and in vitro studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13563620" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Alterations of adrenal steroid patterns in man resulting from treatment with a chemical inhibitor of 11 beta-hydroxylation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2465303" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : The inhibition of human adrenal steroidogenic enzyme activities by suramin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3946973" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Suramin and function of the adrenal cortex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8941013" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Mineralocorticoid insufficiency due to suramin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6247603" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Effects of some clinically encountered drugs on steroid synthesis and degradation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3706393" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Adverse effect of phenytoin on mineralocorticoid replacement with fludrocortisone in adrenal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6490796" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3200786" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Rifampicin-induced adrenal insufficiency in the acquired immunodeficiency syndrome: difficulties in diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2830062" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : The effect of o,p'-DDD on adrenal steroid replacement therapy requirements.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
